SCHEMBL3570566

SCHEMBL3570566

CCN(C)N=C1C=C(F)C(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2ccccc2)=CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
UTS2R Q9UKP6 4/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
EP300 Q09472 4/20 0.37
CNR1 P21554 2/20 0.37
CASR P41180 1/20 0.37
FPR2 P25090 1/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPY5R Q15761 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557282 0.91 UTS2R (0.40) MAPTUTS2RSMN1; SMN2EP300CNR1
SCHEMBL3564011 0.91 UTS2R (0.38) MAPTUTS2RMEN1KMT2ASMN1; SMN2
SCHEMBL3563314 0.90 UTS2R (0.38) MAPTUTS2REP300CNR1CASR
SCHEMBL3573295 0.86 CNR1 (0.39) MAPTUTS2RSMN1; SMN2EP300CNR1
SCHEMBL3567078 0.83 MAPT (0.43) MAPTUTS2RMEN1KMT2ASMN1; SMN2
SCHEMBL3569299 0.82 CNR1 (0.38) MAPTKMT2ASMN1; SMN2GAAEP300
SCHEMBL3565833 0.82 EP300 (0.38) MAPTSMN1; SMN2GAAEP300CNR1
SCHEMBL5813659 0.81 ALDH1A1 (0.37) MAPTUTS2RMEN1KMT2ASMN1; SMN2
SCHEMBL3567403 0.78 CNR1 (0.34) MAPTUTS2RMEN1KMT2ASMN1; SMN2
SCHEMBL5823833 0.75 MAPT (0.35) MAPTUTS2RMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 MAPT 1933/4885UTS2R 52/4885MEN1 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.